Asset Details
Do you wish to reserve the book?
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry
Do you wish to request the book?
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry
2016
Overview
Introduction
Ventricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.
Methods
These are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1–12 months after RDN.
Results
Within 4 weeks prior RDN, a median of 21 (interquartile range 10–30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0–7) (
p
= 0.004) and 0 (
p
= 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.
Conclusions
In patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Anti-Arrhythmia Agents - therapeutic use
/ Heart Failure - complications
/ Heart Failure - physiopathology
/ Humans
/ Male
/ Medicine
/ Postoperative Complications - etiology
/ Sympathectomy - adverse effects
/ Sympathetic Nervous System - physiopathology
/ Sympathetic Nervous System - surgery
/ Tachycardia, Ventricular - diagnosis
/ Tachycardia, Ventricular - etiology
/ Tachycardia, Ventricular - physiopathology
/ Tachycardia, Ventricular - surgery
/ Ventricular Fibrillation - diagnosis
/ Ventricular Fibrillation - etiology
